Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/32721
Title: 5-alpha reductase inhibitors use in prostatic disease and beyond.
Austin Authors: Chislett, Bodie ;Chen, David;Perera, Marlon ;Chung, Eric;Bolton, Damien M ;Qu, Liang G 
Affiliation: Young Urology Researchers Organisation (YURO), Melbourne, VIC, Australia.
Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Urology, Princess Alexandra Hospital, University of Queensland, Brisbane, QLD, Australia.
Urology
Issue Date: 31-Mar-2023
Date: 2023
Publication information: Translational Andrology and Urology 2023; 12(3): 487-496
Abstract: 5-alpha reductase inhibitors (5-ARIs) are commonly used and widely available, with benefits observed from their effect on androgen signalling. Their effect relies on the inhibition of the 5-alpha reductase enzyme which aids in the conversion of testosterone to dihydrotestosterone. 5-ARIs have increasing clinical relevance outside of benign prostatic hyperplasia (BPH). Such development requires clinicians to have an updated review to guide clinical practices. This review details the pharmacology and mechanisms of action for 5-ARIs and how this relates to multiple clinical indications. Of note, is the debunked association between finasteride and increased risk of high-grade prostate cancer. Furthermore, adverse effects of 5-ARI use are detailed in this review, with specific mentions to post-finasteride syndrome. In addition to overviews pertaining to BPH and prostate cancer, much attention has also been focused on severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The androgen axis may be associated with an increased virulence for SARS-CoV-2 in men, with some reporting a correlation between the severity of illness and androgenic alopecia. Since these observations, the role of antiandrogens, including 5-ARIs, has been explored further in SARS-CoV-2. Increasing understanding of pathological processes involving the androgen axis in which 5-ARIs work, has led to increasing clinical indications for 5-ARIs. Several novel off-label indications have been suggested including its potential role in the pathogenesis of SARS-CoV-2, but to date, these claims have not been substantiated. Previously held truths regarding the role of 5-ARIs and prostate carcinogenesis have been contested, inadvertently leading to the re-exploration of 5-ARIs utility in prostate cancer. With growing evidence into pathological processes involving the androgen axis, 5-ARIs are likely to become increasingly more used. This review serves as a timely update of 5 ARIs pharmacology, current indications and potential future directions.
URI: https://ahro.austin.org.au/austinjspui/handle/1/32721
DOI: 10.21037/tau-22-690
ORCID: 
Journal: Translational Andrology and Urology
Start page: 487
End page: 496
PubMed URL: 37032761
Type: Journal Article
Subjects: 5-alpha reductase inhibitors (5-ARIs)
coronavirus disease (COVID)
prostate cancer
review
severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Jul 15, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.